Guslandi M
Institute of Internal Medicine, University of Milan, Italy.
J Int Med Res. 1990 Nov-Dec;18(6):497-505. doi: 10.1177/030006059001800608.
Evidence is accumulating that ursodeoxycholic acid (UDCA), an agent widely employed for gallstone dissolution, exerts therapeutic effects in chronic liver disease. UDCA is thought to act mainly by reducing the detergent properties of bile, making it less toxic for the liver cells. Confirming the results of preliminary observations double-blind, placebo-controlled trials have shown that UDCA significantly decreased serum concentrations of liver enzymes such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and gamma-glutamyl transferase in primary biliary cirrhosis and other cholestatic conditions, as well as in chronic active hepatitis. A substantial improvement in liver histology has also been detected in UDCA-treated patients with primary biliary cirrhosis. The effect of UDCA in chronic hepatitis is currently a matter of investigation.
越来越多的证据表明，熊去氧胆酸（UDCA）这种广泛用于溶解胆结石的药物，在慢性肝病中具有治疗作用。UDCA被认为主要通过降低胆汁的去污剂特性，使其对肝细胞的毒性降低而起作用。双盲、安慰剂对照试验证实了初步观察结果，这些试验表明，在原发性胆汁性肝硬化、其他胆汁淤积性疾病以及慢性活动性肝炎中，UDCA能显著降低血清中谷丙转氨酶、谷草转氨酶、碱性磷酸酶和γ-谷氨酰转移酶等肝酶的浓度。在接受UDCA治疗的原发性胆汁性肝硬化患者中，肝脏组织学也有显著改善。UDCA在慢性肝炎中的作用目前正在研究中。
